Gennaro Pagano

From Top Italian Scientists Wiki
Revision as of 15:58, 16 January 2023 by Admin (talk | contribs) (Created page with "Prof. Gennaro Pagano is a physician-neuroscientist and pharma medical director with over 10 years of experience in translational research and early clinical development. He holds a Doctor of Medicine, Master in Epidemiology, Doctor of Philosophy in Clinical Neuroscience, and has postdoctoral training in PET molecular imaging with a focus on genetics, preclinical, and prodromal Parkinson's disease. He has a h-index of 39 on Google Scholar, and has published over 100 peer-...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Prof. Gennaro Pagano is a physician-neuroscientist and pharma medical director with over 10 years of experience in translational research and early clinical development. He holds a Doctor of Medicine, Master in Epidemiology, Doctor of Philosophy in Clinical Neuroscience, and has postdoctoral training in PET molecular imaging with a focus on genetics, preclinical, and prodromal Parkinson's disease. He has a h-index of 39 on Google Scholar, and has published over 100 peer-reviewed publications in the field of neurodegeneration (common and rare movement disorders, and dementia).[1]

Prof. Pagano currently works as an Expert Medical Director and Group Leader at Roche Pharma Research and Early Development in Switzerland and serves as also the Chair of the Medical Directors Fellowship program in Neuroscience and Rare disease (NRD). He is also Honorary Clinical Associate Professor in Neurology and Neuroimaging at the University of Exeter Medical School, and former Chair of Parkinson's Progressive Markers Initiative (PPMI) Partner Scientific Advisory Board.[2]

Before joining Roche, Gennaro was the Lily Safra Senior Clinical Fellow in Neurology and Research & Development Leader of the Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience at the King’s College London. In this role, he designed, implemented and led several Phase 0, 1 and Phase 2 proof-of-concept trials, and published his research on peer-reviewed International journals, such as New England Journal of Medicine, Lancet Neurology, Movement Disorders, Brain, Neurology, Annals of Neurology, European Journal of Neurology, Journal Clinical Investigation among others.[3]

External links

Placeholder

References